NA
Therapeutic Areas
Immuneering Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMM-1-104 | Advanced solid tumors with MAPK pathway mutations | Phase 1/2a |
| IMM-6-415 | Undisclosed oncology target | Discovery |
| Partnered Program A | Undisclosed oncology target | Not Disclosed |
| Partnered Program B | Undisclosed oncology target | Not Disclosed |
Leadership Team at Immuneering
BZ
Ben Zeskind
Co-Founder, President, Chief Executive Officer, Director
MB
Michael Bookman
Chief Legal Officer, Secretary
H'
Harold 'E.B.' Brakewood
Chief Business Officer
BH
Brett Hall
Chief Scientific Officer
CA
Christian Alaia
Senior Director, Financial Planning & Analysis
DA
Damaris Arcila
Senior Accountant
HA
Hemalatha Athawale
Senior Research Associate